ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks
(Q39052365)
scientific article published on January 2015
scientific article published on January 2015
Language:
Current Data About
ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks
other details
description | scientific article published on January 2015 |
External Links
(P356) |
10.2217/FCA.14.82
|
(P698) |
25606700
|